




1 SUPPLEMENTARY FIGURES

2



3

4 **Supplementary Figure 1: Ipsilateral footpad swelling associated with LAV CHIKV**  
 5 **immunization.** Adult C57Bl/6J mice were immunized with 10<sup>3</sup> PFU CHIKV LAV derivatives  
 6 unless indicated as 10<sup>4</sup> PFU. Hindlimb footpad cross-sectional area was measured as an ellipse  
 7 once daily for 18 days post inoculation (**a**) and total swelling area under the curve (**b**) are shown  
 8 post immunization. *P* < 0.05 (A), 0.001 (C), 0.0001 (D), 2-Way ANOVA on untransformed  
 9 values, n=5 per experiment, 2 combined experiments. Mean and standard deviation are  
 10 indicated with data points/bars and error bars. AUC=Area Under the Curve.



11

12 **Supplementary Figure 2: Mutation accumulation of cell culture-passaged fidelity-variant**  
 13 **CHIKV live-attenuated vaccine candidates.** Positions in genome and frequency of single  
 14 nucleotide polymorphisms acquired over 10 serial passages in BHK-21 cells for each CHIKV  
 15 live-attenuated vaccine are given. Each graph represents a one replicate passage. Dashed line  
 16 is 50% of fragments sequenced, indicating a consensus change for the population. Data are  
 17 percent variance from the reference genome for individual replicates of serially passaged  
 18 CHIKV LAV.

19



26 SUPPLEMENTARY TABLES

27

Primer Name	Pool #	Primer Sequence
CV181-25_1_LEFT	1	GAGACACACGTAGCCTACCAGT
CV181-25_1_RIGHT	1	CGCTTGTAAGTCCCCGATCTTT
CV181-25_2_LEFT**	2	TGTCGGACAGGAAGTACCACTG
CV181-25_2_RIGHT**	2	TTGTTCGAGTATGAGGGGTAGGC
CV181-25_3_LEFT	1	ACCACCAGGCGATTAAAGGAGT
CV181-25_3_RIGHT	1	CACACGAAACCACTGTGTCACA
CV181-25_4_LEFT	2	TGTTCTCAGTAGGGTCAACGCT
CV181-25_4_RIGHT	2	ACCACTATCCTCTGGTTCAGCC
CV181-25_5_LEFT	1	CCGGCGACCATTTGTGATCAAA
CV181-25_5_RIGHT	1	GTCCTCAACGGGATTGACAACC
CV181-25_6_LEFT	2	ACAAGAGGCCTGATACCCAGTC
CV181-25_6_RIGHT	2	CACGACGTGGTCTGTTAGTTGG
CV181-25_7_LEFT	1	CGAAATCGACGTGGAACAGCTT
CV181-25_7_RIGHT	1	CCTCACCAGCTCATACGACTCT
CV181-25_8_LEFT	2	AAAGCGCAACGATGGTGTACAA
CV181-25_8_RIGHT	2	CTCTCTGTCTCATCACGTCGGT
CV181-25_9_LEFT	1	GCAAGTCAGCCATTATCAAGAACC
CV181-25_9_RIGHT	1	CAGTGTACACCGCCTGGAGATA
CV181-25_10_LEFT	2	AGCAGTGCGGCTTCTTCAATAT
CV181-25_10_RIGHT	2	GACGTGCTCTGATGTTGATGCA
CV181-25_11_LEFT	1	ACTGCAAATTGACTATCGTGGACA
CV181-25_11_RIGHT	1	TTATCCCCGCTGTTTCGAGGAT
CV181-25_12_LEFT	2	CATCGATAATGGCGGGCATCTG
CV181-25_12_RIGHT	2	TCCTGGTAGTCACGCAGATCTG
CV181-25_13_LEFT	1	TTCGGATTCAACCCTGAGGCAG
CV181-25_13_RIGHT	1	GGTCATACCTACCAAGCGTTGC
CV181-25_14_LEFT	2	TAAGAGAGTCACCTGGGTAGCG
CV181-25_14_RIGHT	2	AGGCTGCATTTCAGTTGATTGTTCA
CV181-25_15_LEFT	1	GAAACCACCATGTGTCACCAGT
CV181-25_15_RIGHT	1	CCTTTGCGACTTCTCGATAGGC
CV181-25_16_LEFT	2	CGTATCCAGTAATCCACGCCGT
CV181-25_16_RIGHT	2	TTTTCTGCCTGCCAAGCTACTG
CV181-25_17_LEFT	1	CATACAGATGCGGACCCAAGTG
CV181-25_17_RIGHT	1	TGACATGGTTCATGCGAAGTCG
CV181-25_18_LEFT	2	CAGAAATGCCCGGTGGATGATG
CV181-25_18_RIGHT	2	GTAATGTATGTACCGCCCCGTC
CV181-25_19_LEFT	1	AGTTTGATCTAAGCGCCGATGG

CV181-25_19_RIGHT	1	CCTTCGTCTCGAAGTCCCCAAATG
CV181-25_20_LEFT	2	CAGCTATTTCCCTTCAGGCACC
CV181-25_20_RIGHT	2	GGGTAACACTTCTCCTCGTGGA
CV181-25_21_LEFT	1	GAACTGGTCCAGGCCATTTAC
CV181-25_21_RIGHT	1	ACTCATTACATGCTGCCACTGC
CV181-25_22_LEFT	2	CGACTTATCGGACCATATACCCG
CV181-25_22_RIGHT	2	ACTGCTGAGTCCAAAGTGGGTA
CV181-25_23_LEFT	1	ACCTTCCCCATTCCAGAACA
CV181-25_23_RIGHT	1	CATAGGTACGCTGTTGCCAAGG
CV181-25_24_LEFT	2	CAGTAGATATGAAAAGGATGTGAAGGT
CV181-25_24_RIGHT	2	AATCTCTCCGAAAGCAGCCTCT
CV181-25_25_LEFT	1	GCCAAGATGATTCACCTTGCGCT
CV181-25_25_RIGHT	1	GGAGCTTTCTGGGATACAACACTGC
CV181-25_26_LEFT	2	ACATGGTGTCTCGTCTCCGATGAA
CV181-25_26_RIGHT	2	GCAAAGGTGGCCATGGACATTA
CV181-25_27_LEFT	1	GATGGCAACGAACAGGGCTAAT
CV181-25_27_RIGHT	1	CTGAGATCAGCTGGGCAAGTTG
CV181-25_28_LEFT	2	TTCTACAATAGGAGGTACCAGCCT
CV181-25_28_RIGHT	2	ATCGATGGTCCCCTTTACGTGT
CV181-25_29_LEFT	1	TGCATCTTCGAAGTCAAGCATGA
CV181-25_29_RIGHT	1	TACGGGCTCCTTCATTAGCTCC
CV181-25_30_LEFT*	2	TACAGTACTCAGGAGGCCGGTT
CV181-25_30_RIGHT_V2*	2	TGGCTTTATAGACATTGAAGTTGTCC
CV181-25_31_LEFT	1	CGCATGCTAGAAGACAACGTCA
CV181-25_31_RIGHT	1	GCCAGGATGAAGTGTCCCATTG
CV181-25_32_LEFT	2	AATCATATGCCAGCAGACGCAG
CV181-25_32_RIGHT	2	TGTACCGCACCGTCTGACTATT
CV181-25_33_LEFT	1	AGGTACATATGCCCCAGACAC
CV181-25_33_RIGHT	1	TGGTCAGGATACAGCAGCATGA
CV181-25_34_LEFT	2	TCCTCTGGCAAATGTGACATGC
CV181-25_34_RIGHT	2	ATCGACAGGAGTACGAACGAGG
CV181-25_35_LEFT	1	GGCCACCCGCATGAGATAATTT
CV181-25_35_RIGHT	1	CCGACGCTCATTACGGCTAAAA
CV181-25_36_LEFT	2	AACGAGCAGCAGCCTTTGTTTT
CV181-25_36_RIGHT	2	CTCTTGTCCTTGCACTCTGCTG
CV181-25_37_LEFT	1	AGCCAACGCTATCGCTTGATTA
CV181-25_37_RIGHT	1	GTGTCCAGGCTGAAGACATTGG
CV181-25_38_LEFT	2	ACCAAGGAAATAATGTTACTGTATCTGCT
CV181-25_38_RIGHT	2	AGTTCATCGCTCTTACCGGGTT
CV181-25_39_LEFT	1	GGCACCATCTGGCTTCAAGTAT
CV181-25_39_RIGHT	1	ACAGACTTGTACGCGGAATTCCG

CV181-25_40_LEFT	2	TAACGCCGTCACTATTCGGGAA
CV181-25_40_RIGHT_V2	2	GGGACACATATACCTTCGTACC
CV181-25_41_LEFT	1	GCAGCACTGATCCTAATCGTGG
CV181-25_41_RIGHT	1	AGCCCTTTGAACTACTTCTGTTTATGG
CV181-25_42_LEFT_V2**	2	GAGACACACCATATATAGCTAAGAATCAAT
CV181-25_42_RIGHT**	2	ACCTACATCTCTTCCGTTTGCC

28

29 **Supplementary Table 1. Primers used for PrimalSeq amplicon-based sequencing of**  
30 **CHIKV-181/25 genomes.** Primers were generated using PrimalScheme wrapper for Primer3  
31 multiplex primer design tool targeting the CHIKV-181/25 full-length genome<sup>47</sup>. Variant (V2)  
32 primers were modified manually to account for gaps in CHIKV-181/25-P2.P4.E3/E1 and regions  
33 of high similarity in conserved repeat elements present in the CHIKV 3'-UTR. All primers were  
34 pooled with equal volumes of 10 µM starting concentration unless noted otherwise (\* 50 µM, \*\*  
35 100 µM).

<b>Score</b>	<b>Short Description</b>	<b>Long Description</b>
<b>0</b>	none	no lesions observed
<b>1</b>	minimal	focal or scattered, minimal, subcutaneous inflammation and/or edema not observed in control animals or of questionable significance; could be a background lesion or variation of normal
<b>2</b>	mild	mild inflammation of subcutaneous tissue, fascia, and/or skeletal muscle affecting less than 10% of the soft tissue surrounding tarsus/metatarsus/digit, and/or moderate to severe edema of subcutaneous tissue
<b>3</b>	moderate	mild to moderate inflammation and edema of subcutaneous tissue, fascia, skeletal muscle, and/or tendon affecting 10-25% of the soft tissue surrounding tarsus/metatarsus/ digit; and/or scattered myocyte necrosis; and/or synovial cell reactive hyperplasia
<b>4</b>	severe	widespread, severe inflammation and edema of subcutaneous tissue, fascia, skeletal muscle, and/or tendon affecting greater than or equal to 25% of the soft tissue surrounding tarsus/metatarsus/digit, and/or more widespread myocyte necrosis; and/or synovial cell reactive hyperplasia or mild synovial/peri-synovial inflammation
<b>5</b>	severe with evidence of joint lesions	same as "4" but with more severe inflammation; and/or inflammation/necrotic debris in the joint space; and/or lesions affecting articular cartilage or bone

36

37 **Supplementary Table 2: Pathology scoring criteria.**